215 related articles for article (PubMed ID: 1333738)
1. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
[TBL] [Abstract][Full Text] [Related]
2. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan.
Chen CH; Shih JF; Lindholm-Levy PJ; Heifets LB
Am Rev Respir Dis; 1989 Oct; 140(4):987-9. PubMed ID: 2552883
[TBL] [Abstract][Full Text] [Related]
3. Minimal inhibitory concentrations of lomefloxacin and minocycline against drug-sensitive and drug-resistant isolates of M. tuberculosis compared on L-J and 7H11 media.
Kamala T; Herbert D; Venkatesan P; Paramasivan CN
Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):375-8. PubMed ID: 9401493
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Sulochana S; Rahman F; Paramasivan CN
J Chemother; 2005 Apr; 17(2):169-73. PubMed ID: 15920901
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
Rastogi N; Goh KS
Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872
[TBL] [Abstract][Full Text] [Related]
6. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
Foroumadi A; Soltani F; Moshafi MH
Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J
Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
[TBL] [Abstract][Full Text] [Related]
8. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
9. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
10. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
[TBL] [Abstract][Full Text] [Related]
11. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
Casal M; Ruiz P; Herreras A
Int J Tuberc Lung Dis; 2000 Jun; 4(6):588-91. PubMed ID: 10864193
[TBL] [Abstract][Full Text] [Related]
12. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
Beskid G; Prosser BL
Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; Climent A; Royo G
Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
[TBL] [Abstract][Full Text] [Related]
14. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
Yamane N; Chilima BZ; Tosaka M; Okazawa Y; Tanno K
Kekkaku; 1996 Aug; 71(8):453-8. PubMed ID: 8831190
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of lomefloxacin as compared with ciprofloxacin.
Inderlied CB; Lancero MG; Bermudez LM; Young LS
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):17S-20S. PubMed ID: 2791493
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.
Ruiz-Serrano MJ; Alcalá L; Martínez L; Díaz M; Marín M; González-Abad MJ; Bouza E
Antimicrob Agents Chemother; 2000 Sep; 44(9):2567-8. PubMed ID: 10952620
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Karak K; De PK
Indian J Med Res; 1995 Apr; 101():147-9. PubMed ID: 7751043
[TBL] [Abstract][Full Text] [Related]
19. [In vitro antimycobacterial activity of a new quinolone, T-3761].
Tomioka H; Sato K; Saito H
Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
